| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5424286 | ASTRAZENECA AB | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
Dec, 2016
(7 years ago) | |
| US6858576 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Jan, 2017
(7 years ago) | |
| US7741269 | ASTRAZENECA AB | Exendins and exendin agonists for weight reduction and obesity |
Jan, 2018
(6 years ago) | |
| US6956026 | ASTRAZENECA AB | Use of exendins for the reduction of food intake |
Jan, 2018
(6 years ago) | |
| US6872700 | ASTRAZENECA AB | Methods for glucagon suppression |
Jan, 2020
(4 years ago) | |
| US6667061 | ASTRAZENECA AB | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
| US6495164 | ASTRAZENECA AB | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
| US6479065 | ASTRAZENECA AB | Process for the preparation of polymer-based sustained release compositions |
Aug, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US7223440 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Aug, 2021
(2 years ago) | |
|
US7223440 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(2 years ago) | |
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(1 year, 6 months ago) | |
|
US6824822 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(1 year, 11 days ago) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(4 days ago) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(4 days ago) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 2 months from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 8 months from now) | |
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 11 months from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
| US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(3 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(4 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(4 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
Bydureon is owned by Astrazeneca Ab.
Bydureon contains Exenatide Synthetic.
Bydureon has a total of 46 drug patents out of which 17 drug patents have expired.
Expired drug patents of Bydureon are:
- US5424286
- US6858576
- US7741269
- US6956026
- US6872700
- US6667061
- US6495164
- US6479065
- US9198925
- US6936590
- US7223440
- US7223440*PED
- US6824822
- US6824822*PED
- US9238076
- US7563871
- US6414126
Bydureon was authorised for market use on 27 January, 2012.
Bydureon is available in for suspension, extended release;subcutaneous dosage forms.
Bydureon can be used as as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin, reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4, reductions in body weight are observed with exenatide, reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin, as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea, as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication, improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise, treating type 2 diabetes mellitus with exenatide by stimulating insulin release, treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
The generics of Bydureon are possible to be released after 26 May, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| New Patient Population(NPP) | Jul 22, 2024 |
| M(M-240) | Feb 15, 2022 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| New Product(NP) | Jan 27, 2015 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4; Reductions in bo...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON family patents
